Annexon (NASDAQ:ANNX - Free Report) had its price objective reduced by Needham & Company LLC from $16.00 to $11.00 in a report issued on Tuesday,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.
Annexon Stock Up 11.0%
Shares of NASDAQ ANNX traded up $0.20 during midday trading on Tuesday, hitting $2.01. 1,761,522 shares of the company's stock were exchanged, compared to its average volume of 1,783,396. The firm has a market capitalization of $220.53 million, a PE ratio of -1.91 and a beta of 1.24. Annexon has a 12 month low of $1.29 and a 12 month high of $7.85. The company's 50 day moving average price is $1.91 and its 200 day moving average price is $3.65.
Annexon (NASDAQ:ANNX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.07). On average, equities research analysts anticipate that Annexon will post -0.96 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC boosted its holdings in shares of Annexon by 212.0% during the third quarter. Barclays PLC now owns 177,765 shares of the company's stock worth $1,052,000 after acquiring an additional 120,789 shares during the period. Hennion & Walsh Asset Management Inc. lifted its holdings in Annexon by 65.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 429,584 shares of the company's stock worth $2,204,000 after purchasing an additional 170,180 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Annexon in the 4th quarter valued at $116,000. Rhumbline Advisers grew its holdings in Annexon by 4.3% in the 4th quarter. Rhumbline Advisers now owns 141,852 shares of the company's stock valued at $728,000 after buying an additional 5,854 shares in the last quarter. Finally, New York State Common Retirement Fund grew its holdings in Annexon by 143.4% in the 4th quarter. New York State Common Retirement Fund now owns 34,479 shares of the company's stock valued at $177,000 after buying an additional 20,311 shares in the last quarter.
Annexon Company Profile
(
Get Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Further Reading
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
